GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OSTO:VIVE) » Definitions » Cyclically Adjusted Book per Share

Vivesto AB (OSTO:VIVE) Cyclically Adjusted Book per Share : kr1.50 (As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is Vivesto AB Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Vivesto AB's adjusted book value per share for the three months ended in Mar. 2025 was kr0.279. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr1.50 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Vivesto AB's average Cyclically Adjusted Book Growth Rate was -14.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -5.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Vivesto AB was -2.40% per year. The lowest was -5.60% per year. And the median was -3.55% per year.

As of today (2025-06-28), Vivesto AB's current stock price is kr0.2285. Vivesto AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was kr1.50. Vivesto AB's Cyclically Adjusted PB Ratio of today is 0.15.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vivesto AB was 4.75. The lowest was 0.10. And the median was 1.29.


Vivesto AB Cyclically Adjusted Book per Share Historical Data

The historical data trend for Vivesto AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Cyclically Adjusted Book per Share Chart

Vivesto AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.97 1.88 1.86 1.75 1.58

Vivesto AB Quarterly Data
Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.75 1.70 1.63 1.58 1.50

Competitive Comparison of Vivesto AB's Cyclically Adjusted Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vivesto AB's Cyclically Adjusted PB Ratio falls into.


;
;

Vivesto AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vivesto AB's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.279/132.8245*132.8245
=0.279

Current CPI (Mar. 2025) = 132.8245.

Vivesto AB Quarterly Data

Book Value per Share CPI Adj_Book
201504 2.400 99.941 3.190
201507 0.000 100.027 0.000
201510 2.150 100.301 2.847
201601 2.028 99.931 2.696
201604 1.901 100.732 2.507
201607 1.688 101.080 2.218
201610 1.761 101.485 2.305
201701 1.503 101.326 1.970
201704 1.489 102.615 1.927
201707 1.547 103.301 1.989
201710 1.465 103.202 1.885
201801 1.358 102.925 1.753
201804 1.288 104.390 1.639
201807 1.182 105.420 1.489
201810 1.345 105.545 1.693
201901 1.155 104.855 1.463
201904 1.123 106.627 1.399
201907 1.132 107.166 1.403
201910 1.077 107.243 1.334
202001 1.612 106.215 2.016
202004 1.827 106.240 2.284
202007 1.715 107.731 2.114
202010 1.592 107.539 1.966
202103 1.426 108.360 1.748
202106 1.300 108.928 1.585
202109 1.231 110.338 1.482
202112 1.226 112.486 1.448
202203 1.325 114.825 1.533
202206 1.147 118.384 1.287
202209 1.014 122.296 1.101
202212 0.606 126.365 0.637
202303 0.567 127.042 0.593
202306 0.514 129.407 0.528
202309 0.485 130.224 0.495
202312 0.368 131.912 0.371
202403 0.352 132.205 0.354
202406 0.333 132.716 0.333
202409 0.314 132.304 0.315
202412 0.294 132.987 0.294
202503 0.279 132.825 0.279

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Vivesto AB  (OSTO:VIVE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vivesto AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.2285/1.50
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vivesto AB was 4.75. The lowest was 0.10. And the median was 1.29.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Vivesto AB Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB Business Description

Industry
Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.